Obesity drugs may spur licensing, distribution deals for Indian drugmakers after patent expires
The rising demand for obesity drugs is prompting Indian pharma firms to pursue licensing and distribution partnerships, particularly for GLP-1 drugs. Major deals have been signed, with analysts predicting continued growth in the market as patents expire and supply chain collaborations emerge.
The rising demand for obesity drugs is prompting Indian pharma firms to pursue licensing and distribution partnerships, particularly for GLP-1 drugs. Major deals have been signed, with analysts predicting continued growth in the market as patents expire and supply chain collaborations emerge.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
